{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63","upperLimit":"84","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"description":"PD from European Bone Marrow Transplant (EBMT) Response Criteria Required one or more:\n\n\\>25% increased in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation, or \\>25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation), or \\>25% increased in plasma cells in a bone marrow aspirate or biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.\n\nDevelopment of new bone lesions or soft tissue plasmacytomas (not including compression fracture).\n\nDevelopment of hypercalcemia (corrected serum calcium \\>11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).\n\nPFS was measured from treatment initiation to progression or death, censored at the date patients were last known to be alive and disease free","dispersionType":"95% Confidence Interval","groups":[{"id":"OG000","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"This numbers excluded 2 patients who went off study prior to start of therapy.","reportingStatus":"POSTED","timeFrame":"PFS rate at 18 months","title":"Estimated 18-month Progression Free Survival (PFS) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}